Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
Sanofi and Cipla partner to expand reach of CNS portfolio in India
While Sanofi maintains ownership responsibilities for its entire CNS product line, Cipla will utilize its extensive network of marketing and sales professionals, and outreach programs across India to enhance patient access to these treatments.
- By PharmaNews Live Desk
- New Delhi
- Mar 27, 2024
Sanofi India Limited and Sanofi Healthcare India Private Limited, collectively known as Sanofi India, have teamed up with Cipla Limited in an exclusive collaboration aimed at distributing and promoting Sanofi India's Central Nervous System (CNS) product range in India. Under this agreement, Cipla will oversee the distribution of six CNS brands, including Frisium®, an anti-epileptic medication.
While Sanofi India maintains ownership, importation, and manufacturing responsibilities for its entire CNS product line, Cipla will utilize its extensive network of marketing and sales professionals, distributors, institutions, and outreach programs across India to enhance patient access to these treatments.
Rodolfo Hrosz, Managing Director of Sanofi India Limited, remarked, “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve the lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.”
Achin Gupta, Chief Executive Officer of Cipla Limited's One India Business, added, “Enhancing access to high-quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients.”
This collaboration aligns with Sanofi India’s ongoing plans to accelerate its innovation pipeline in India, spanning various therapeutic areas such as diabetes, transplants, rare diseases, consumer healthcare, and vaccines.